Transgenic mice with both alies of the p53 tumor suppressor gene (frequently mutaed in human tumors) knocked out by gene tarting provide a potialy useful tumorigenesis mode because these mice rapidly develop spontaneous tumors. To determine whether tumorigenesis In p53-knokout mice is sie to experimental mapult, tumor development in response to calorie t on (CR; a potent inhibitor of rodent tumors) was evaluated. Tumor development was monitored for 48 weeks in male nullizygous p53-knockout and wild-type littermate mice (28-30 per treatment group) fed ad libitum (AL) or restricted to 60% ofAL carbohydrate calorie intake. CR:p53-knockout mice (median survival =25 weeks) experienced a delay in tumor onset and subsequent mortality (P = 0.0002) relative to AL:p53-knockout mice (median survival = 16 weeks). Tumor development and mortality in wildtype liffermates on either diet treatment were <4% through 48 weeks. Cell cycle analyses were performed on splenocytes from p53-knockout mice and wild-type littermates after 4 weeks ofAL feeding or CR (5 per group). The percentage of splenocytes in S phase of the cell cycle was 3-fold higher for p53-kkout mice than wild-type mice (P < 0.001), and CR reduced the percentage of S-phase splenocytes in both p53-knockout and wild-type mice (P = 0.012). These data demonstrate that tumor development in p53-knockout mice genetically predisposed to tumors can be delayed by CR (possibly via cell cycle modulation) and suggest that these mice provide a very useful model of spontaneous tumorigenesis.
ABSTRACT
Transgenic mice with both alies of the p53 tumor suppressor gene (frequently mutaed in human tumors) knocked out by gene tarting provide a potialy useful tumorigenesis mode because these mice rapidly develop spontaneous tumors. To determine whether tumorigenesis In p53-knokout mice is sie to experimental mapult, tumor development in response to calorie t on (CR; a potent inhibitor of rodent tumors) was evaluated. Tumor development was monitored for 48 weeks in male nullizygous p53-knockout and wild-type littermate mice (28-30 per treatment group) fed ad libitum (AL) or restricted to 60% ofAL carbohydrate calorie intake. CR:p53-knockout mice (median survival =25 weeks) experienced a delay in tumor onset and subsequent mortality (P = 0.0002) relative to AL:p53-knockout mice (median survival = 16 weeks). Tumor development and mortality in wildtype liffermates on either diet treatment were <4% through 48 weeks. Cell cycle analyses were performed on splenocytes from p53-knockout mice and wild-type littermates after 4 weeks ofAL feeding or CR (5 per group). The percentage of splenocytes in S phase of the cell cycle was 3-fold higher for p53-kkout mice than wild-type mice (P < 0.001), and CR reduced the percentage of S-phase splenocytes in both p53-knockout and wild-type mice (P = 0.012). These data demonstrate that tumor development in p53-knockout mice genetically predisposed to tumors can be delayed by CR (possibly via cell cycle modulation) and suggest that these mice provide a very useful model of spontaneous tumorigenesis.
Mutation of the p53 tumor suppressor gene is the most frequently observed genetic lesion in human cancer (1, 2) . Over 50% of all human tumors examined to date have identifiable p53 gene point mutations or deletions (3) . In addition, p53 mutations are associated with the Li-Fraumeni syndrome, a familial autosomal dominant disease characterized by increased susceptibility to a variety of tumors (4) .
The accumulation of p53 protein in response to DNA damage induces a cell cycle arrest in the G1 phase that appears to allow time for repair of damaged DNA prior to entry into S phase (5, 6) . Acting as a transcription factor, p53 turns on the expression of WAFi/Cipl, the 21-kilodalton protein product of which can mediate the p53-induced arrest of the cell cycle (7) . If the repair process in damaged cells is unsuccessful, p53 can trigger apoptotic cell death, at least in some cell types (8) . Cells in which p53 is inactivated lack this cell cycle checkpoint control for DNA damage and are genetically less stable (9) . The viability of mature nullizygous p53 "knockout" (p53-/-) mice, with both alleles of the p53 gene inactivated by gene targeting techniques (10) , implies that the p53 protein is unnecessary for normal growth and development. However, p53-/-mice are highly susceptible at an early age to a variety of spontaneous tumors (10), a further confirmation of the tumor-suppressing role of p53.
Given the frequency of p53 mutations in human tumors, p53-/-mice provide an attractive tumorigenesis model since tumor development in these mice is rapid and spontaneous. The purpose of the present study was to determine if tumorigenesis in p53-/-mice is responsive to dietary manipulation, specifically to calorie restriction (CR), a welldocumented inhibitor of tumors in several species and a multiplicity of tumor types (11) (12) (13) . In addition, because CR has been shown to decrease mitotic rates in a variety of normal and neoplastic tissues (14, 15) The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (16) . Differences in survival were compared using Cox proportional hazards analysis (17) . Splenocyte Cell Cycle Analysis. An additional group of 10 male p53-/-mice and 10 male p53+/+ littermates was randomized to AL or CR regimens (5 per group). These mice were killed with CO2 following 4 weeks of diet treatment and splenocytes were isolated as described (9) . In brief, spleens were aseptically removed and placed in cold RPMI 1640 medium (GIBCO). Individual 
RESULTS
The growth curves of the p53-/-mice on either dietary regimen were virtually identical to the growth curves of the p53+/+ mice through the first 15 weeks of study (Fig. 1) average body weights of the p53-/-mice showed some fluctuations after this time due to the onset of tumor development in a large proportion of the group. CR mice, regardless of p53 status, were significantly smaller (P < 0.01) than AL mice throughout the study period.
Marked differences were seen in the survival curves for the respective treatment groups (Fig. 2) . As expected, very little tumor development or mortality was observed in p53+/+ mice on either diet treatment through the 48-week study period. In contrast, all p53 -/-mice were dead by 37 weeks of study.
However, CR:p53-/-mice showed a statistically significant delay in tumor-related mortality relative to AL:p53-/-mice (P = 0.0002), based on Cox proportional hazards analysis (17) . Median (Tables 2 and 3 ). Lymphomas were the most commonly observed tumors; 61% of tumor-bearing AL:p53-/-mice and 79% of tumor-bearing CR:p53-/-mice developed malignant lymphoma. The majority of lymphomas occurring in p53-/-mice on either diet treatment were of lymphoblastic origin, although 25-30% were of immunoblastic or follicular center cell origin and an additional 15-30% were pleomorphic (morphologic evidence of both T-and B-cell elements in the same animal (Tables 2 and 3) . Twenty-six AL:p53-/-mice died from malignant tumor development and one died from intussusception due to a cecal adenoma. The cause of death for the three remaining mice in this group appeared to be infection, based on histopathologic evidence. Twenty-three CR:p53-/-mice died from malignant tumor development. Of the remaining five CR:p53-/-mice, one died from intestinal blockage due to intussusception; the cause of death could not be determined for the other four mice. Among the p53+/+ mice, one AL-fed animal died from spontaneous lymphoma development during the 48-week study period. Three other AL:p53+/+ mice died tumor-free; one displayed histopathologic evidence of 18 
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Tumor types or causes of death were not statistically different between AL-fed or CR p53-knockout mice at P < 0.05. (11) (12) (13) , including spontaneous lymphomas in C57BL/6 mice, the main background strain of the mice used in the present study (19 development observed in the CR:p53-/-mice, relative to AL:p53-/-mice, suggests that the wild-type p53 tumor suppressor gene is not an absolute requirement for the tumor-suppressive effects of CR. These data also demonstrate that a dietary perturbation (i.e., CR) can influence the outcome of a genomic liability such as the accelerated tumorigenesis displayed by p53-knockout mice.
The findings from our cell cycle studies may provide insights into the predisposition of p53-/-mice to spontaneous lymphoma development as well as the tumor-suppressing effects of CR. Lymphoid cells, which undergo programed DNA rearrangements of the immunoglobulin genes, appear to be particularly susceptible to the loss of p53 (20, 21) . Although our cell cycle analyses are limited by small sample sizes (n = 5 mice per group) and incomplete analyses of cell cycle parameters (Thornthwaite procedure; ref. 18) , the data suggest that splenocytes from AL:p53-/-mice have a higher percentage of S-phase cells relative to splenocytes from AL:p53+/+ mice. This finding is consistent with a report that embryonic fibroblasts derived from p53-/-mice also have a higher percentage of cells in S phase than embryonic fibroblasts from p53+/+ mice (20) . Premature entry of lymphocytes into S phase before the correct gene rearrangements are completed could result in aberrant recombination events that are potentially mutagenic (20, 21) . In addition, lymphocytes from p53-/-mice would lack the p53-mediated apoptotic pathway and might thus exhibit increased survival of lymphoid precursors with abnormal rearrangements (21) . This could explain why inactivation of the p53 gene results in a high incidence of lymphoma in p53-/-mice derived from strains with a high background incidence of lymphoma, such as the predominantly C57BL/6 strains (this study; refs. 10 and 20) and a pure 129/Ola strain (21) , as well as in p53-/-mice derived from 129/Sv mice, a strain with a low background incidence of lymphoma (20) .
Our data also indicate that CR decreases (by 20-30%6) the percentage ofS-phase splenocytes in both p53-/-and p53+/+ mice, consistent with previous reports of reduced mitotic activity in a variety of tissues in response to CR (14, 15) . Elucidation of the mechanisms underlying the observed effects of CR on spontaneous tumor development and splenocyte cell cycle in p53-/-mice may reveal some important intervention targets that can be exploited in the development of cancer prevention strategies to counteract the increased risk of cancer seen with loss of p53 tumor suppressor gene function. To our knowledge, there has been no previous report of an experimental treatment that suppresses tumor development in p53-/-mice, which (because of germ-line inactivation of the p53 gene) are genetically predisposed to early spontaneous tumorigenesis. The mechanistic pathways in p53-/-mice responsible for modulated tumor development should have relevance to human cancer, since mutations in the p53 gene are the most common genetic lesions observed in human tumors (1) (2) (3) . In addition, tumor development in these mice is spontaneous, thus eliminating the need for carcinogens or other agents to induce tumorigenesis, and is rapid, with untreated p53-/-mice showing 50%6 mortality due to malignant tumors by about S months of age. Finally, the demonstration of a delay in tumor development in p53-/-mice in response to experimental manipulation suggests that these mice provide a useful model of spontaneous tumorigenesis.
